Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Critical Issues in Treating HIV During Pregnancy

Landsberger1

  • 1High-Risk Obstetrics Clinic at The New York Hospital-Cornell Medical Center, New York City, NY.

Medscape Women'S Health
|June 1, 1996
PubMed
Summary

Zidovudine (AZT) significantly reduces perinatal HIV transmission by two-thirds when administered to mothers during pregnancy and labor, and to newborns. This treatment is crucial for preventing mother-to-child HIV transmission.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ground-state photoneutron reactions in 14C.

Physical review. C, Nuclear physics·1985
Same author

High spin states in 99Tc.

Physical review. C, Nuclear physics·1985
See all related articles

Area of Science:

  • Virology
  • Obstetrics
  • Public Health

Background:

  • HIV infection in pregnant women presents unique challenges for transmission prevention.
  • Understanding the timing and mechanisms of vertical HIV transmission is critical for intervention.
  • Maternal HIV viral load is a key predictor of perinatal transmission risk.

Purpose of the Study:

  • To evaluate the efficacy of zidovudine (AZT) in reducing perinatal HIV transmission.
  • To investigate the impact of pregnancy on HIV progression.
  • To explore the relationship between maternal viral load and HIV transmission.

Main Methods:

  • Administration of zidovudine (AZT) to HIV-infected pregnant women during pregnancy and labor.
  • Administration of zidovudine (AZT) to newborns for six weeks post-delivery.
  • Monitoring of maternal and infant HIV status and viral load.

Main Results:

  • Zidovudine (AZT) regimen reduced perinatal HIV transmission by two-thirds.
  • Pregnancy was not found to accelerate HIV progression.
  • Vertical HIV transmission can occur as early as 8 weeks gestation.
  • Maternal HIV resistance to zidovudine can lead to transmission of resistant strains.
  • High maternal viral load (>80,000 RNA copies/mL) correlated with 100% transmission, while low viral load (<20,000 copies/mL) correlated with 0% transmission.
  • Zidovudine treatment led to an 8-fold median decrease in plasma RNA levels.

Conclusions:

  • The zidovudine (AZT) regimen is highly effective in preventing mother-to-child HIV transmission.
  • Maternal viral load is a critical factor in predicting transmission risk.
  • Monitoring viral load and managing zidovudine resistance are important components of perinatal HIV prevention.

Related Experiment Videos